Florida Fails to Pass Amendment Legalizing Recreational Weed
By Robin Foster HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- A ballot measure to legalize the recreational use of marijuana in the state of Florida failed on Tuesday.
While 55.9% of Florida voters backed the proposed amendment, it did not reach the 60% threshold needed to make the initiative part of the state's constitution.
"With the rejection of Amendment 3, Floridians have taken a firm stance against the dangerous drugs the pot profiteers tried to convince the public are harmless," Kevin Sabet, president of Smart Approaches to Marijuana, which opposes marijuana legalization, said in a statement.
“Amendment 3 was bad for Florida and even worse for Floridians,” Mark Wilson, president and CEO of the Florida Chamber of Commerce, said in a statement. “This pro-drug amendment was bad for our kids, bad for our communities, bad for our local business, and ultimately bad for Florida.”
David Culver, senior vice president of the U.S. Cannabis Council, told the Washington Post that the supermajority threshold required by Florida was too much to overcome this election.
“This isn’t the end in Florida, it’s just the beginning since we’ve now seen how strongly the push for legalization resonates in the state,” Culver added.
Florida wasn't the only state to say no to recreational marijuana this election: Voters in North Dakota and South Dakota appear to have again rejected similar measures, the Post reported.
Meanwhile, voters in Nebraska handily approved two measures legalizing medical marijuana, though a judge could invalidate those results in the coming weeks, the Post reported.
Psychedelics, which have been touted by some as a potential treatment for depression and other mental health issues, also took a hit in the polls: In Massachusetts, voters rejected a measure that would have legalized plant psychedelics such as magic mushrooms for therapeutic use. Oregon and Colorado have already passed such laws, the Post reported.
At the moment, recreational marijuana is legal in 24 states and Washington, D.C., amid dramatic shifts in public attitudes about the drug. Gallup polling last year reported that a record 70% of voters support marijuana legalization.
Although marijuana remains illegal at the federal level, the Biden administration is seeking to loosen restrictions, but skeptics argue that high-potency marijuana products pose a risk to youth brain development and up the chances for addiction.
The Biden measure would not legalize marijuana at the federal level, but instead place it in the less dangerous tier of controlled substances that includes prescription ketamine and testosterone. That move could boost research into marijuana’s health benefits by easing federal restrictions for studying the drug.
Sources
- Washington Post
- Florida Chamber of Commerce, news release, Nov. 6, 2024
- Smart Approaches to Marijuana, statement, Nov. 6, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Vaping Is A Gateway To Smoking, Evidence Says
THURSDAY, Aug. 21, 2025 — Vaping appears to act as a gateway to cigarette smoking among young people, a new evidence review says. E-cigarettes also were significantly...
Taking One Step Can Boost Your Odds Of Kicking A Drug Habit
FRIDAY, Aug. 15, 2025 — Folks fighting an addiction can boost their chances of success if they also drop the smokes, a new study says. Addicts who quit smoking have up to...
FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products
TUESDAY, July 29, 2025 -- The U.S. Food and Drug Administration is recommending that certain products containing 7-hydroxymitragynine (7-OH) -- an illegal opioid easily accessible...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.